Latest Avanir Pharmaceuticals Inc (AVNR) Headlines
Avanir (AVNR) Catches Eye: Stock Soars 16.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:25AM CST
Avanir was a big mover last session, as the company saw its shares rise over 16% on the day.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AVANIR Pharmaceuticals Up 5.5%, Shares Break Through Resistance (AVNR)
Comtex SmarTrend(R) - Wed Mar 05, 10:12AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 5.5% to $4.54 on 1.0x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.1 million shares, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Avanir Pharmaceuticals to Participate in Two Conferences in March
PR Newswire - Fri Feb 28, 8:00AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
Hot Stock: AVANIR Pharmaceuticals, Shares Gain 6.5% (AVNR)
Comtex SmarTrend(R) - Wed Feb 26, 11:41AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 6.5% to $4.09 on 1.3x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.5 million shares, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (6.5% to the Dow's 0.3%) and outperformed the S&P 500 (6.5% to the S&P's 0.3%) during today's trading.
Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 7:00AM CST
Avanir Pharmaceuticals had high hopes for AVP-923, a neuropathy pain treatment for Alzheimer's, Parkinson's, and autism. However, AVP-923 failed to do better than placebo in a key mid-stage multiple sclerosis trial, disappointing investors and...
Will Mallinckrodt's Xartemis Change How We Treat Pain?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 14, 12:36PM CST
is having a stellar run since being spun-off by Covidien last summer. The split-up is unlocking value at both companies as Covidien focuses on its medical device business and Mallinckrodt advances new pain killing compounds to market. So far,...
4 New Issues IPO Investors Need to Know About for This Week
Eric Volkman, The Motley Fool - Motley Fool - Sun Feb 09, 1:00PM CST
The IPO train continues to thunder noisily down the track. According to Renaissance Capital, so far this year 27 fresh stock issues have been priced, a tally nearly 60% higher than at the same point last year. And 2013 was a tough act to follow,...
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Feb 07, 3:00PM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new employees to purchase a total of 48,400 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).
Moms Demand Action Releases Its Take On Facebook Anniversary Videos With A "Closer Look" At Gun Sales On The Social Network
PR Newswire - Fri Feb 07, 10:58AM CST
On the heels of Facebook's 10th anniversary and the "look back" videos that have dominated newsfeeds this week, Moms Demand Action for Gun Sense in America today released its own riff on the videos to take a "closer look" at how Facebook makes it easy for guns to be bought and sold online - without criminal background checks. The video can be viewed at www.DemandAction.org/Facebook
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Avanir Pharmaceuticals' Revenue Soars 62% on Strong Nuedexta Sales
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 4:28PM CST
Avanir Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported strong product sales growth in its first-quarter earnings results after the bell today. For the quarter,...
Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results
PR Newswire - Wed Feb 05, 3:00PM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013.
Avanir Files NDA for AVP-825 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 4:20PM CST
Avanir submitted a New Drug Application to the FDA for its migraine candidate, AVP-825
Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migraine
PR Newswire - Thu Jan 30, 8:00AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine.
Analysis of the ANZ RFID Market
PR Newswire - Thu Jan 30, 6:40AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
3 Companies Working on Parkinson's Treatments You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 29, 1:52PM CST
Parkinson's Disease effects between 7 million and 10 million patients worldwide. Roughly 60,000 new cases will be diagnosed in the United States this year alone, yet despite that big unmet need drug makers have stumbled in their attempts to bring...
Avanir Pharmaceuticals Announces Date of Fiscal 2014 First Quarter Financial Results and Conference Call
GlobeNewswire - Tue Jan 28, 7:30AM CST
Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended December 31, 2013 after market close on Wednesday February 5, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Pharma Industry Technical Data: Zoetis, Avanir Pharma, Actavis, and Salix Pharma
PR Newswire - Thu Jan 16, 6:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
Avanir (AVNR) Catches Eye: Stock Soars 16.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:25AM CST
Avanir was a big mover last session, as the company saw its shares rise over 16% on the day.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AVANIR Pharmaceuticals Up 5.5%, Shares Break Through Resistance (AVNR)
Comtex SmarTrend(R) - Wed Mar 05, 10:12AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 5.5% to $4.54 on 1.0x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.1 million shares, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (5.5% to the Dow's -0.1%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Avanir Pharmaceuticals to Participate in Two Conferences in March
PR Newswire - Fri Feb 28, 8:00AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
Hot Stock: AVANIR Pharmaceuticals, Shares Gain 6.5% (AVNR)
Comtex SmarTrend(R) - Wed Feb 26, 11:41AM CST
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's best performing low-priced stocks, up 6.5% to $4.09 on 1.3x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 2.5 million shares, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (6.5% to the Dow's 0.3%) and outperformed the S&P 500 (6.5% to the S&P's 0.3%) during today's trading.
Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 7:00AM CST
Avanir Pharmaceuticals had high hopes for AVP-923, a neuropathy pain treatment for Alzheimer's, Parkinson's, and autism. However, AVP-923 failed to do better than placebo in a key mid-stage multiple sclerosis trial, disappointing investors and...
Will Mallinckrodt's Xartemis Change How We Treat Pain?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 14, 12:36PM CST
is having a stellar run since being spun-off by Covidien last summer. The split-up is unlocking value at both companies as Covidien focuses on its medical device business and Mallinckrodt advances new pain killing compounds to market. So far,...
4 New Issues IPO Investors Need to Know About for This Week
Eric Volkman, The Motley Fool - Motley Fool - Sun Feb 09, 1:00PM CST
The IPO train continues to thunder noisily down the track. According to Renaissance Capital, so far this year 27 fresh stock issues have been priced, a tally nearly 60% higher than at the same point last year. And 2013 was a tough act to follow,...
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Feb 07, 3:00PM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new employees to purchase a total of 48,400 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).
Moms Demand Action Releases Its Take On Facebook Anniversary Videos With A "Closer Look" At Gun Sales On The Social Network
PR Newswire - Fri Feb 07, 10:58AM CST
On the heels of Facebook's 10th anniversary and the "look back" videos that have dominated newsfeeds this week, Moms Demand Action for Gun Sense in America today released its own riff on the videos to take a "closer look" at how Facebook makes it easy for guns to be bought and sold online - without criminal background checks. The video can be viewed at www.DemandAction.org/Facebook
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Avanir Pharmaceuticals' Revenue Soars 62% on Strong Nuedexta Sales
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 4:28PM CST
Avanir Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported strong product sales growth in its first-quarter earnings results after the bell today. For the quarter,...
Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results
PR Newswire - Wed Feb 05, 3:00PM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013.
Avanir Files NDA for AVP-825 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 4:20PM CST
Avanir submitted a New Drug Application to the FDA for its migraine candidate, AVP-825
Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migraine
PR Newswire - Thu Jan 30, 8:00AM CST
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine.
Analysis of the ANZ RFID Market
PR Newswire - Thu Jan 30, 6:40AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
3 Companies Working on Parkinson's Treatments You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 29, 1:52PM CST
Parkinson's Disease effects between 7 million and 10 million patients worldwide. Roughly 60,000 new cases will be diagnosed in the United States this year alone, yet despite that big unmet need drug makers have stumbled in their attempts to bring...
Avanir Pharmaceuticals Announces Date of Fiscal 2014 First Quarter Financial Results and Conference Call
GlobeNewswire - Tue Jan 28, 7:30AM CST
Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended December 31, 2013 after market close on Wednesday February 5, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Pharma Industry Technical Data: Zoetis, Avanir Pharma, Actavis, and Salix Pharma
PR Newswire - Thu Jan 16, 6:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
